Great, but too slow and too late; huge opportunity may have been...

Great, but too slow and too late; huge opportunity may have been wasted.

The early success at Mount Sinai hospital under an FDA approved emergency treatment program should have been the catalyst to get a similar approval for an emergency treatment program back in Aus; particularly when revealed that the new executive director at Victor Chang recently spent 11 years at Mount Sinai.

At this very moment we could/should have been presenting similar successful results further strengthening the Mount Sinai results and cementing Mesoblast’s treatment in a position of dominance; very disappointing.

I would highly recommend getting the emergency treatment approval ASAP (if not already done) and get treating critical patients STAT.

I DON’T KNOW, conduct a trial if you must, BUT, this window of opportunity, if not closed, is closing fast.

I DON’T KNOW, what would it mean, if for example Mesoblast could report critical patients cured and leaving Hospitals next weekend?